The drug sensitivity and DTG‐S correlation analysis executed in HER2‐negative breast cancer cell lines showed that the higher DTG‐S cells were more sensitive to paclitaxel, docetaxel, and doxorubicin, which is consistent with the preceding clinical analysis results. Here, ERBB2 is linked to breast carcinoma.